Gerard Caelles

Gerard Caelles has a diverse work experience in the biotech industry. Gerard has held various roles in different companies over the years.

Gerard'smost recent position is as the Chief Business Officer at SpliceBio, a biotechnology company focused on developing gene therapies using protein splicing technology. The company raised $57 million in a Series A financing round and has partnerships with venture firms and pharmaceutical companies.

Prior to their role at SpliceBio, Gerard worked at ProteoDesign, which later evolved into SpliceBio. During their time there, they played a crucial role in the company's pivot to gene therapy and its subsequent seed and Series A financings. Gerard held the position of Director, Corporate Strategy & Business Development.

Before joining ProteoDesign, Gerard worked as an Advisor to the CEO at Luqa Pharmaceuticals, a medical aesthetics biotech company based in China. Gerard provided support to the CEO with due diligence for a series B financing and identified new market opportunities to increase revenue.

Gerard also has experience at Bionure, now known as Accure Therapeutics. Gerard started as one of the early employees in the company and contributed to the development of the main program from the discovery stage to filing an IND for a Phase 1 trial in neuro-ophthalmology. Gerard later supported the CEO in fundraising and led business development discussions.

Additionally, Gerard had a research trainee position at Oryzon, where they gained hands-on experience in protein purification and characterization. This experience helped him realize that they did not want to pursue a lab-based career.

Overall, Gerard Caelles has a strong background in business development, strategy, and corporate leadership within the biotech industry.

Gerard Caelles completed their education in a chronological order. Gerard first attended the Universitat Autònoma de Barcelona from 2008 to 2012, where they earned a Bachelor of Science degree in Biotechnology. Following this, in 2013, they enrolled at Hexagrama - Chinese School of Barcelona and completed the HSK3 program, which focuses on Chinese language proficiency. In 2016, Gerard briefly attended CELforPharma, where they pursued a course on Pharma-Biotech Product and Company Valuation. Additionally, in 2015, they obtained a certification in Corporate Finance from Coursera Verified Certificates.